awmsg logo



adalimumab (Humira®)


Reference No. 2571

Publication date:
10/12/2015


Appraisal information

adalimumab (Humira®) 40 mg/0.8 ml solution for injection


Company: AbbVie Ltd
BNF category: Skin
NMG meeting date: 07/10/2015
AWMSG meeting date: 11/11/2015
   
   
Submission Type: Limited Submission
Status: Superseded
Advice No: 3615
Ministerial ratification: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA455) NICE GUIDANCE ISSUED JULY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download